Healthcare Industry News: cord blood
News Release - March 3, 2006
Group Successfully Improves Life of Youngest-Ever Stroke Patient to be Treated with Umbilical Cord Stem CellsSHENZHEN, China, March 3 (HSMN NewsFeed) -- Shenzhen Beike Biotechnology Co., Ltd. has announced the successful treatment with umbilical cord stem cells of the youngest stroke patient ever to undergo such a procedure. The announcement was made following a two-month evaluation period by physicians in her native country, Hungary, to verify the positive results.
Starting from October 28th, Beike provided umbilical cord stem cells to the Nanshan People's Hospital for the treatment of a four-month-old Hungarian baby girl named Timea Gresco, who had suffered a stroke when she was delivered three months prematurely. Umbilical cord stem cells were delivered intravenously over a two-month time period. Due to national regulations, the baby could not receive such treatment in her own country so her mother, Judit Godo, traveled to Shenzhen with her husband and daughter.
Treatments for leukemia and other diseases with umbilical cord blood stem cells have been performed for years. However, the treatment of stroke patients and those with other neurological diseases with stem cells from human umbilical cords has become increasingly popular only recently. Today, treatments for neurological diseases using umbilical cord blood is being taken forward by countries outside the United States, including China, as FDA approval takes longer.
Timea was born on July 16th, 2005 and immediately suffered a stroke - with bleeding on the left side of her brain causing significant brain damage. She was able to move all of her limbs, but the left limbs had significantly less strength than the right and the doctors predicted she would have both physical and mental impairment including possible paralysis when older. When she finished her treatment, all her limbs had gained strength with the left having nearly the same strength as the right.
"At first we were doubtful about Timea getting stem cell treatments in China. Over time, our doubt turned into curiosity," said Timea's physician in Hungary. "Time will tell but we were quite surprised to see how active the baby was upon her return from China. This is not common for babies with such severe brain damage."
Mrs. Godo said, "As a mother, I knew Timea was getting improvement as soon as she stopped crying after the first injection, but it was reassuring to see such a positive reaction from the medical staff when I returned home.
"Before the treatment, Timea was crying all the time, never smiled and would not acknowledge you if you smiled or waved at her. After the treatment, she stopped crying, started smiling a lot, smiles back at you - even through a mirror, and has a healthy appetite which she did not before. All her limbs were stronger and her affected arm and leg have become almost as strong as her healthy ones. After coming home, her head control keeps improving and she no longer keeps her head to one side," said Ms. Godo.
Dr. Sean Hu, chairman of Beike, said, "We were all very happy to see the improvement. In theory, the younger you are when you receive stem cell treatments, the more effective, but we were excited to see such positive results so quickly. This is the youngest patient we have treated and while we can't say positively, as far as we know, this is the youngest patient in the world treated for stroke with umbilical cord blood stem cells. We look forward to having Timea back for another treatment before she turns one."
About Beike Biotech Company Limited
Beike is a biotechnology company that was founded with capital from Beijing University, Hong Kong University of Science and Technology and Shenzhen City Hall. It is also supported with funds from the China State National Fund. The research and clinical work is a collaboration of Beijing University, Hong Kong University of Science and Technology, No. 3 Army Medical University, Zhongshan Medical University, Guiyang Medical College and Zhengzhou University.
Source: Beike Biotechnology
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.